Histone deacetylases and epigenetic therapies of hematological malignancies
- 26 February 2010
- journal article
- review article
- Published by Elsevier in Pharmacological Research
- Vol. 62 (1), 18-34
- https://doi.org/10.1016/j.phrs.2010.02.010
Abstract
No abstract availableKeywords
This publication has 206 references indexed in Scilit:
- Genome-wide Mapping of HATs and HDACs Reveals Distinct Functions in Active and Inactive GenesCell, 2009
- Histone deacetylase inhibitors: Potential in cancer therapyJournal of Cellular Biochemistry, 2009
- Targeting tumor angiogenesis with histone deacetylase inhibitorsCancer Letters, 2008
- Epigenomic profiling of cancer cellsThe International Journal of Biochemistry & Cell Biology, 2008
- The aggresome pathway as a target for therapy in hematologic malignanciesMolecular Genetics and Metabolism, 2008
- The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and menNature Reviews Molecular Cell Biology, 2008
- Sirtuins in mammals: insights into their biological functionBiochemical Journal, 2007
- Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitorProceedings of the National Academy of Sciences, 2006
- Anticancer activities of histone deacetylase inhibitorsNature Reviews Drug Discovery, 2006
- Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancerNature Reviews Cancer, 2006